According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

SAN FRANCISCO -- Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) versus a single drug, a large randomized trial showed.

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Cancer research continues to evolve as scientists strive to unravel the complexities of tumor biology, molecular signaling, and metabolic adaptations.

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

SAN FRANCISCO -- The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant ...

Claire Conley, PhD, and Marcelo Sleiman, Jr., discuss the need for protocols in supporting patients’ psychosocial needs.

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...